DNA Polymerase Delta 1 Catalytic Subunit (POLD1) as a Prognostic Factor in Clear Cell Renal Cell Carcinoma Patients

Background/Aim: DNA polymerase delta 1 catalytic subunit (POLD1 or POLD1/p125) plays a crucial role in DNA synthesis and proofreading during the semiconservative genome replication. Mutations of POLD1 are associated with abnormal cell division in various human tumors. However, the significance of altered POLD1 expression in malignant diseases and its usefulness as a prognostic factor is not fully understood. This study aimed to determine POLD1 immunoexpression levels in paired sections of tumor and normal kidney derived from 56 patients with clear cell renal cell carcinoma (ccRCC) and evaluate the significance of POLD1 protein as a potential prognostic factor in ccRCC. Materials and Methods: Tissue samples were collected from 56 patients (27 females and 29 males, mean age 62.6, range=27-83 years) who underwent nephrectomy due to ccRCC. Paired tissue samples were obtained from the tumor and unchanged part of the kidney. The expression of POLD1 protein was assessed by immunohistochemistry. Clinical and pathological data of patients were also collected. Patients were followed-up and the median time of observation period was 39.3 months. Results: The study revealed a significantly higher POLD1 nuclear expression in ccRCC tumor tissue samples and this was correlated with longer survival rates (better prognosis) of ccRCC patients. Conclusion: POLD1 immunoreactivity in ccRCC postoperative material could be helpful as a prognostic marker in the ccRCC patient group.

[1]  Shuai Zhao,et al.  Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma , 2021, Frontiers in Genetics.

[2]  N. Vogelzang,et al.  Biomarkers in renal cell carcinoma: Are we there yet? , 2021, Asian journal of urology.

[3]  Zhijie Liang,et al.  Resveratrol Mediates the Apoptosis of Triple Negative Breast Cancer Cells by Reducing POLD1 Expression , 2021, Frontiers in Oncology.

[4]  Lemeng Zhang,et al.  Multiple microarray analyses identify key genes associated with the development of Non-Small Cell Lung Cancer from Chronic Obstructive Pulmonary Disease , 2021, Journal of Cancer.

[5]  Y. Pavlov,et al.  DNA Polymerases at the Eukaryotic Replication Fork Thirty Years after: Connection to Cancer , 2020, Cancers.

[6]  Tariq Ahmad Masoodi,et al.  POLE and POLD1 pathogenic variants in the proofreading domain in papillary thyroid cancer , 2020, Endocrine connections.

[7]  B. Drozdzowska,et al.  Correlation among different pathologic features of renal cell carcinoma: a retrospective analysis of 249 cases. , 2020, International journal of clinical and experimental pathology.

[8]  Tariq Ahmad Masoodi,et al.  POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East , 2020, Molecular genetics & genomic medicine.

[9]  C. Sundaram,et al.  Differentiation of renal cell tumors with morphological cocktails using a minimal panel of immunohistochemical markers , 2020, Urology annals.

[10]  Tariq Ahmad Masoodi,et al.  Germline POLE and POLD1 proofreading domain mutations in endometrial carcinoma from Middle Eastern region , 2019, Cancer Cell International.

[11]  R. Xu,et al.  Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. , 2019, JAMA oncology.

[12]  Lorenzo Marconi,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.

[13]  N. Agarwal,et al.  Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. , 2019, Annals of translational medicine.

[14]  A. Ceribelli,et al.  Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC , 2018, AntiCancer Research.

[15]  Guiqin Zhang,et al.  Abnormally high expression of POLD1, MCM2, and PLK4 promotes relapse of acute lymphoblastic leukemia , 2018, Medicine.

[16]  E. Golemis,et al.  POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies , 2016, Gene.

[17]  B. Delahunt,et al.  Best Practices Recommendations in the Application of Immunohistochemistry in the Kidney Tumors: Report From the International Society of Urologic Pathology Consensus Conference , 2014, The American journal of surgical pathology.

[18]  K. Eckert,et al.  Eukaryotic Replicative DNA Polymerases , 2014 .

[19]  B. Delahunt,et al.  Renal Tumors: Diagnostic and Prognostic Biomarkers , 2013, The American journal of surgical pathology.

[20]  J. Cheville,et al.  The International Society of Urological Pathology (ISUP) Grading System for Renal Cell Carcinoma and Other Prognostic Parameters , 2013, The American journal of surgical pathology.

[21]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[22]  L. Loeb,et al.  DNA polymerase delta in dna replication and genome maintenance , 2012, Environmental and molecular mutagenesis.

[23]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[24]  B. Delahunt Advances and controversies in grading and staging of renal cell carcinoma , 2009, Modern Pathology.

[25]  F. Erdoğan,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.

[26]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.